Collagen Matrix, Inc. Selected to Participate in FDA’s Experiential Learning Program
Collagen Matrix, Inc. Selected to Participate in FDA’s Experiential Learning Program
Collagen Matrix, Inc., a leading provider of high quality products and technology used in tissue repair and regeneration announced today it has been selected to participate in the Food and Drug Administration’s Experiential Learning Program (ELP). The ELP is designed to provide the FDA’s Center for Devices and Radiological Health (CDRH) review staff with real-world experience in the design, manufacture and use of medical devices.
The program’s learning approach offers CDRH staff an opportunity to explore device technology and obtain knowledge to enhance the review process and support communication between sponsors and review staff. In response to FDA’s request for industry participation specifically in the area of Bone Grafting Materials for Dental Applications, Collagen Matrix’s site visit proposal was selected for this year’s ELP training, which will take place at the company’s headquarters in Oakland, New Jersey.
“We are pleased to be among the companies selected to participate in the ELP to provide FDA reviewers with a view of the proprietary design, development and manufacture of collagen- and mineral-based medical devices from industry’s perspective,” said Bart Doedens, CEO of Collagen Matrix.
Founded in 1997, Collagen Matrix has expanded beyond the sales of its first product, a collagen membrane used in oral surgery, to include the sales of over 55 medical devices in more than eighty countries worldwide. Specifically in the area of oral surgery, Collagen Matrix is the manufacturer and supplier of premier collagen membranes and bone graft materials to the clinical community through its marketing and distribution relationships with strong large and mid-size dental companies having established worldwide distribution channels.
About Collagen Matrix
Collagen Matrix, Inc. is a driving force in the design and engineering of collagen- and mineral-based extracellular matrices for tissue and organ repair and regeneration. Since its inception in 1997, the Company has received many government grants for the development of innovative, collagen-based matrix products in the areas of neurological, vascular, urological, and orthopedic tissue regeneration applications. The Company currently manufactures collagen-based finished medical devices in the areas of oral/maxillofacial surgery, neurosurgery, and orthopedic-spine surgery. For more information about the Company, please visit www.collagenmatrix.com.